New Whitepaper Compares Targeted Resequencing Strategies
News Jul 17, 2013
Oxford Gene Technology (OGT) has produced a new, free-to-download whitepaper titled ‘When to use targeted resequencing - Choosing the right NGS method.’
The paper aims to assist researchers when planning NGS strategies by providing a detailed review of the major resequencing methods.
Comparing and contrasting method suitability, the paper also examines the significant impact of data analysis, as well as time and cost considerations.
OGT has written the whitepaper in response to a growing demand from within its customer base and the NGS community for a balanced and comprehensive guide to targeted resequencing strategies.
Considered from both clinical research and discovery viewpoints, the paper discusses whole exome and targeted panel sequencing strategies, without bias.
This includes highlighting the limitations of each approach, and offering advice on when whole genome sequencing is appropriate, providing researchers with insight to identify the most suitable method for the task at hand.
Considerations are also presented on choice of capture technologies, bait design and the use of service providers for method optimization and accessibility to meaningful results.
Single-stranded Origami Technology Drives Drug Delivery Systems and Pharmaceutical Nanofactories ForwardNews
First nanotechnological approach enables the design and replication of complex single-stranded DNA and RNA origami with potential for drug delivery and nanofabrication.READ MORE
Cracking the Code of Coenzyme Q BiosynthesisNews
Coenzyme Q is a vital cog in the body’s energy-producing machinery, a kind of chemical gateway in the conversion of food into cellular fuel. Researchers are developing new tools to shed light on CoQ function, primarily by finding and defining proteins that have a direct link to the chemical. This includes the development of a new multi-omic strategy to identify the global function of an RNA-binding protein that has long been associated with mitochondria and its role in CoQ biosynthesis.READ MORE
First Successful Gene Therapy Trial Reported for People with Hemophilia ANews
Patients with hemophilia A who received a single infusion of an investigational gene therapy showed improved levels of the essential blood clotting protein FVIII, with 11 of 13 achieving normal or near-normal FVIII levels.READ MORE